We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cáncer de mama triple negativo: terapias sistémicas actuales y experiencia local.
- Authors
Glomaryeth Luque S.; Benjamin Walbaum G.; Mauricio Camus A.; Francisco Domínguez C.; Tomas Merino L.; Francisco Acevedo C.; César Sánchez R.
- Abstract
Breast cancer is the leading cause of cancer death in Chilean women and worldwide. It is a heterogeneous disease and four different subtypes have been identified based on clinical, histological and molecular features, which correlate with different treatment tumor sensitivity. Triple negative breast cancer is characterized by its aggressiveness, early relapse, and a greater tendency to present in advanced stages. It frequently affects young women, with cancer family history, especially breast or ovarian cancer. The approved systemic therapy for triple negative breast cancer is chemotherapy; however, recently, targeted therapies with checkpoint inhibitors and polyadenosine diphosphate ribose polymerase inhibitors have been shown to be effective in selected patients and have been added to the therapeutic arsenal for triple negative breast cancer. Given the appearance of these new strategies, it seems relevant to understand the heterogeneity of this disease, the mechanisms of action behind new therapies, clinical results, and the criteria to select patients for molecular therapies. We present a review of the current systemic therapy of this breast cancer subtype.
- Publication
Revista de Cirugia, 2021, Vol 73, Issue 2, p188
- ISSN
2452-4557
- Publication type
Article
- DOI
10.35687/s2452-45492021002942